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Abstract
Background: We intended to assess the risk for health care workers (HCWs) of acquiring M. tuberculosis
infection after exposure to patients with sputum-smear positive pulmonary tuberculosis at three University
Hospitals (Ullevål, Akershus, and Haukeland) in Norway.
Methods: We tested 155 exposed health care workers and 48 healthy controls both with a tuberculin skin test
(Mantoux) and the T-SPOT.TB test, a recently developed interferon-γ release assays based on the M. tuberculosis-
specific ESAT-6 and CFP10 antigens, to investigate if this test might improve infection control measures.
Results: Among the 155 exposed HCWs tested in this study, 27 individuals were defined as newly infected cases
by TST after recent exposure, while only 3 of these had a positive T-SPOT.TB test. The number of T-SPOT.TB
positives represents 11% of the individuals defined as recently infected by TST after exposure (3/27) and 2% of
the total number of exposed people tested (3/155). In addition, 15 individuals had been previously defined as
infected by TST before exposure of whom 2 subjects were T-SPOT.TB positive. All individuals detected as T-
SPOT.TB positive belonged to the TST positive group (> 15 mm), and the percentage concordance between T-
SPOT.TB and TST, including both previously and newly infected subjects, was 12% (5/42). The 48 control
participants used in the study were all T-SPOT.TB negative, but 3 of these subjects were TST positive.
Conclusion: Our data indicate that the frequency of latent TB in the total cohort of HCWs is 3%, whereas the
rate of transmission of TB to exposed individuals is approximately 2% and occurs through exposure periods of
short duration. Thus, the risk of TB transmission to HCWs following TB exposure in a hospital setting in Norway
is low, and improved screening approaches will benefit from the application of specific interferon-γ release assays.
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Background
In Norway the incidence of tuberculosis (TB) is generally
low, and surveillance is primarily based on the detection
and treatment of latent infection in risk groups and con-
tact tracing following exposure. It is well established that
most of the infected individuals will not progress to active
disease, but will maintain a latent infection. Although a
latent infection is clinically silent and not contagious, it
can reactivate to cause highly contagious pulmonary
tuberculosis, the most prevalent form of the disease in
adults [1]. Several studies have concluded that transmis-
sion is usually caused by prolonged contact with an infec-
tious case of TB, and the risk of being infected is
dependent upon the amount of time spent sharing room
air with the index case [2]. Still, contact tracing utilizing
the fingerprinting methods IS6110-restriction fragment
length polymorphism (RFLP) and spoligotyping indicate
that a substantial proportion of TB cases acquire infection
as a result of casual exposures of short duration [3].
Health care workers are constantly at risk of exposure, and
reliable and specific diagnostic tools are essential to
improve follow-up procedures. As most new infections
result in latent TB infection, strain fingerprinting can not
be used to trace transmission.
The current policy in Norwegian health institutions is to
perform environmental screenings based on the Mantoux
Tuberculin Skin Test (TST) after TB exposure. According to
international guidelines, individuals with a TST > 5 mm in
non-vaccinated persons and TST > 10 mm in persons vac-
cinated with Bacillus Calmette-Guérin (BCG) are consid-
ered to be infected with M. tuberculosis. In Norway, BCG
vaccination is routinely offered to TST-negative children at
the age of 14 years. In addition, it has been compulsory
for all health care workers to be vaccinated with BCG if a
positive TST has not been documented. Thus, in Norway
the TST status of health care workers is usually known and
the post-exposure TST is compared to the pre-exposure
TST based on the increase in the size of the induration. In
accordance with the national guidelines, the definition of
post-exposure infection is an increase in TST induration of
≥ 10 mm or a TST of ≥ 15 mm if previous TST status is un-
known [4]. Norwegian hospital personnel defined as
infected are followed up with consultations and annual
chest x-rays for three years. In addition, if an employee is
likely infected, prophylactic treatment is offered. A major
problem in many hospitals is that the same personnel
have undergone multiple screenings, which result in
boosting of their TST response. Thus, due to both low spe-
cificity and TST-induced boosting [5], a large proportion
of the group defined as infected after exposure are proba-
bly false positives. This may lead to incorrect treatment,
waste of resources, and unnecessary anxiety.
However, recently developed interferon-γ release assays
(IGRAs), based on the Mtb-specific antigens ESAT-6 and
CFP10, have contributed to improved specificity in TB
screening. These RD1-encoded protein antigens are absent
from all vaccine strains of M. bovis BCG and most non-
tuberculous mycobacteria (except M. marinum, M. szulgai,
M. Kansasii). Such tests can therefore distinguish Mtb
infection from infections caused by other mycobacteria or
previous BCG vaccination [5,6]. Two commercially avail-
able and regulatory agency approved test systems can be
used: T-SPOT.TB  (Oxford Immunotec) is an ELISPOT
assay based on the analysis of a defined number of iso-
lated peripheral blood mononuclear cells, whereas Quan-
tiferon-TB Gold (QFT) (Cellestis) is a whole blood in-tube
ELISA-based test. The tests have comparable specificity
(98–99%), but sensitivity is reported to be somewhat
higher for the T-SPOT.TB test (97%) compared to the QFT
assay (90%). This difference is primarily pronounced in
immuno-suppressed persons and in children, where the
frequency of indeterminate results is demonstrated to be
higher for the QFT assay [7,8].
The specificity of IFN-γ release assays has the potential to
improve both the diagnosis of TB in infected individuals
and the utilisation of public health resources for TB con-
trol. In this study, we have compared the T-SPOT.TB test
with TST in hospital personnel exposed to TB. We have
used the results to assess the role of IFN-γ release assays for
improved screening of this target group, and determine
the rate of TB transmission during short exposure in a TB
low-endemic country.
Methods
Study groups and design
From March 2005 to January 2007, 155 TB-exposed
health care workers were included from three major Uni-
versity Hospitals in Norway: Haukeland University Hos-
pital (HUS), Ullevål University Hospital (UUS), and
Akershus University Hospital (AHUS). For inclusion in
the study, exposed persons had to be in close contact (stay
in the same room) with a sputum-smear positive pulmo-
nary TB patient in a non-protected manner for at least 1
hour. Subjects were then grouped according to the time of
exposure: 'Low exposure' was defined as 1 to 8 cumulative
hours of close contact, while more than 8 cumulative
hours of close contact was considered to be 'high expo-
sure'.
A control group of 48 non-exposed individuals were
recruited from the non-clinical staff at AHUS. Only indi-
viduals without any known prior exposure where
included in this group. The epidemiological data are sum-
marized in Table 1. The mean age of the control group was
41 years, with a female:male ratio of 33:15. The exposed
group was a mean age of 39 years, with a female:male
ratio of 132:22. Ten employees came from TB high-
endemic countries. Both groups lived in the same geo-
graphical area and consisted of employees at NorwegianBMC Infectious Diseases 2009, 9:60 http://www.biomedcentral.com/1471-2334/9/60
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hospitals with middle incomes. The exposed group was
followed up according to the national guidelines, includ-
ing TST and chest X-ray independent of the T-SPOT.TB test
result [4]. All participants answered a questionnaire con-
cerning BCG vaccination status, former TB, previous expo-
sure, and residency in TB high-endemic countries.
Previous studies have demonstrated that individuals
infected with TB complete their cellular immune response
within 8 weeks after exposure [9]. Thus, both the T-
SPOT.TB test and the TST were performed as close to 8
weeks after exposure as possible (mean, 11.5 weeks). The
subjects had not been tested previously by IFN-γ test, so
their pre-exposure T-SPOT.TB status was not known. The
last documented TST found in the hospital records and
TST results obtained 8 weeks after exposure were used as
the basis for determining infection status. The study was
approved by the Regional Committee for Medical
Research Ethics East (REK Øst). Informed consent was
obtained from all participants, clarifying that follow up
and treatment would be offered regardless of participation
and according to national guidelines [4].
Tuberculin skin test
TSTs of both exposed personnel and controls were per-
formed according to the Mantoux method with Purified
Protein Derivate (PPD) RT 23 SSI, (2 TU) from SSI,
Copenhagen, Denmark. Transverse induration in mm at
the injection site was measured after 48–72 hours, and the
results were interpreted according to the national guide-
lines [4]. Reading of test results was repeated if the indu-
ration was large, showed signs of adverse reactions, or was
difficult to read.
T-SPOT.TB test
The T-SPOT.TB test, (Oxford Immunotec, UK), was used
according to the manufacturer's instructions. The blood
was always drawn prior to the TST to avoid any possible
interactions caused by rapid homing of specific T-lym-
phocytes to the tuberculin injection site. Venous blood
drawn into Cell Preparation Tube (CPT) vacutainers
(Beckton Dickinson, Oxford, UK) was sent by courier
service and analysed within 6 hours. In brief, peripheral
blood mononuclear cells (PBMC) were isolated from
blood following centrifugation, washed and counted.
PBMCs at a concentration of 250,000 cells/well in AIM V®
cell culture medium (Invitrogen Corporation, Carlsbad,
USA) were stimulated with ESAT-6 and CFP10 in 96-well
plates pre-coated with anti-IFN-γ capture antibodies, and
incubated overnight at 37°C in 5% CO2. Medium only
and mitogen (Phytohemagglutinin) were used as negative
and positive controls, respectively. The next day the T-
SPOT.TB assay was developed by adding an alkaline phos-
phatase-conjugated detection antibody and substrate.
Coloured spots, representing individual INF-γ-producing
T cells, were counted manually using a microscope. The
results were recorded based on the definition of positive
and negative reactions given in the instructions from the
manufacturer. All initial positive results were confirmed
by analysis of a second blood sample before they were
reported as positive.
Data handling and statistical analysis
All data were entered into a central Microsoft Access™
database, approved by the Norwegian Data Inspectorate,
Table 1: Infection status versus age, sex, migration, exposure time, and Mantoux status
Characteristics New
TST positives
HCWs (n = 27)
Previously defined as TST 
positive
HCWs (n = 15)
TST negatives HCWs 
(n = 113)
Healthy Controls
(n = 48)
Age (years, mean (range)) 38.9 (22–65) 38.9 (22–65) 38.9 (22–65) 41.4 (20–67)
Sex (female/male) 22/5 12/3 98/15 33/15
Migration
1. Born in a low-endemic area 25 12 101 48
2. Worked in a high-endemic area 
> 6 months
00 6
3. Born in a high-endemic area 2 2 6
Exposure time (≤ 8 h/> 8 h) 20/7 10/4 84/29
Mantoux (mm) before exposure 
(median)
8 6/13 5/4
Mantoux (mm) after exposure 
(median)
19 6/6
Vesiculous Mantoux after 
exposure
8
*Results in absolute numbers from post-exposure screening of 155 health care workers (HCWs) and 48 healthy controls, 2005–2007. During 
childhood all participants were either BCG-immunized or had a naturally positive tuberculin skin test (TST). The definition of a positive TST 
(Mantoux) was an increase of ≥ 10 mm, or of ≥ 15 mm if previous TST status was unknown (in concordance with the national guidelines). Some 
HCWs had been defined as TST positive during previous post-exposure screenings (15), while others were defined as infected during the current 
study (27).BMC Infectious Diseases 2009, 9:60 http://www.biomedcentral.com/1471-2334/9/60
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and statistical analysis was performed with the Graph Pad
Prism 4™ software.
Results
Among the 155 exposed health care workers tested, 27
individuals were defined as newly infected cases by TST
after recent exposure, while only 3 of these had a positive
T-SPOT.TB test (Table 2 and 3). There were no indetermi-
nate test results, and no excluded HCWs or T-SPOT.TB
results. The number of T-SPOT.TB  positives represents
11% of the individuals defined as recently infected by TST
after exposure (3/27) and 2% of the total number of
exposed people tested (3/155). In addition, 15 individu-
als had been previously defined as infected by TST before
exposure of whom 2 were T-SPOT.TB positive: one was
born in a TB high-endemic country, and the other had
been previously treated for pulmonary TB. Interestingly,
the former had a negative TST at the time of immigration
to Norway, raising a question concerning the source and
place of infection.
All individuals detected as T-SPOT.TB positive belonged
to the TST positive group, and the percentage concordance
between T-SPOT.TB and TST, including both previously
and newly infected subjects, was 12% (5/42). Two out of
these five individuals were born in a TB high-endemic
country. Thus, according to the T-SPOT.TB results the fre-
quency of latent TB in the total cohort was 3% (5/155),
whereas the TB transmission rate in the actual TB exposure
study was estimated to be 2% (3/155). The 48 control par-
ticipants were all T-SPOT.TB negative, but 3 persons in the
control group were TST positive.
The distribution of TST results, given by mm induration,
within the exposed and control group is given in Figure 1.
A higher frequency of exposed HCWs with an induration
of more than 14 mm was seen. A majority of the healthy
controls had an induration of less than 6 mm.
The average time between first exposure and testing was
11.5 weeks. Among the exposed individuals, 51 partici-
pants belonged to the "high exposure" group (> 8 hours),
and 104 participants fell into the "low exposure" group (≤
8 hours) (Table 1). There was no correlation between
length of exposure and TST results. In addition, there was
no correlation between T-SPOT.TB  positivity and TST
results. For the 3 T-SPOT.TB positive individuals infected
after known exposure, two were exposed ≤ 8 hours and
one was exposed > 8 hours.
Discussion and conclusion
A positive TST has previously been considered the gold
standard in screening for M. tuberculosis infection. How-
ever, there is currently no definitive way to decide whether
a person is latently infected with M. tuberculosis. A recent
prevalence study by Soborg et al. in a Danish hospital con-
firmed earlier findings that TST is hampered by low specif-
icity in BCG-vaccinated individuals [10,11]. The authors
found a 34% prevalence among TST-positive HCWs, but
the only significant risk factor associated with a positive
TST was prior BCG immunisation; no association was
observed with other important risk factors, such as occu-
pational exposure to TB or hospital staff position [10].
Other low-endemic country studies have also found that
a positive TST test is primarily associated with prior BCG
vaccination and the boostering effect of prior TST testing
[12-15]. Nevertheless, how can we conclude that the low
post-exposure rate of infection detected by T-SPOT.TB in
our study represents the real situation if there is no gold
standard? One possible strategy is to estimate the likeli-
hood of having latent TB infection by calculating a contact
score that quantifies exposure to and infectiousness of the
index case, as was done by Shams et al. [16]. A range of
other studies also provide extensive evidence that the
IGRAs correlate better to exposure than does TST. There-
fore, we based our conclusions regarding the prevalence
of TB infections on the T-SPOT.TB test [5,12-14,16-21].
Of 155 exposed HCWs and 48 healthy controls, all but
one had a visible scar from BCG immunisation, which has
been compulsory in Norway at the age of 14 until
recently. Norwegian legislation also demands that all
HCWs are asked for a certificate of TST at the time of
appointment, and if the existence of a recent TST cannot
Table 2: Concordance between TST and T-SPOT.TB Results
Characteristics New TST positives Previously defined as TST positives Total
TST positives among exposed (%) 27/155 (17%) 15/155 (10%) 42/155 (27%)
T-SPOT.TB -positives among exposed (%) 3/155 (2%) 2/155 (1%) 5/155 (3%)
T-SPOT.TB -positives among TST positives (%) 3/27 (11%) 2/15 (13%) 5/42 (12%)
Table 2 depicts concordance between tuberculin skin test (TST) and T-SPOT.TB results. Results in absolute numbers (percentages in brackets) 
from post-exposure screening of 155 health care workers (HCWs) and 48 healthy controls, 2005–2007. During childhood all participants were 
either BCG-immunized or had a naturally positive TST. The definition of a positive TST (Mantoux) was an increase of ≥ 10 mm, or of ≥ 15 mm if 
previous TST status was unknown (in concordance with the national guidelines). The exposed HCWs were also tested with T-SPOT.TB, an 
interferon-gamma release assay (IGRA). Some HCWs had been defined as TST positives during previous post-exposure screenings (15) while 
others were defined as TST positives during the current study (27).BMC Infectious Diseases 2009, 9:60 http://www.biomedcentral.com/1471-2334/9/60
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Table 3: Characteristics of the 5 T-SPOT.TB-positive HCWs
Characteristics HCW 1 HCW 2 HCW 3 HCW 4 HCW 5
Mantoux (mm) median pre/
post exposure
Previously TST positive 12 mm and vesicular 16 mm and vesicular Previous tuberculosis 15 mm and vesicular
TST positive Not tested Yes Yes Not tested Yes
Exposure time (≤ 8 h/> 8 h) ≤ 8 h ≤ 8 h ≤ 8 h ≤ 8 h > 8 h
Table 3 depicts the characteristics of the 5 HCWs with a positive T-SPOT.TB. Results in absolute numbers from post-exposure screening of 155 
health care workers (HCWs) and 48 healthy controls, 2005–2007. During childhood all participants were either BCG-immunized or had a naturally 
positive tuberculin skin test (TST). The definition of a positive TST (Mantoux) was an increase of ≥ 10 mm, or of ≥ 15 mm if previous TST status 
was unknown (in concordance with the national guidelines). The exposed HCWs were also tested with T-SPOT.TB, an interferon gamma release 
assay (IGRA).
be documented then a new TST is performed. The high
correlation between BCG vaccination and a positive TST
and the high specificity of the T-SPOT.TB  test for Mtb
infection (98%) make it likely that these are mostly false
positive TST reactions rather than false negative T-
SPOT.TB results. In addition, as found by Nienhaus et al.
[14], the boosting effect of repetitive skin testing in health
personnel may also contribute to the somewhat surpris-
ingly low concordance between infection status according
to T-SPOT.TB and TST that was observed in this study
(12%). Still, there is no diagnostic gold standard for latent
TB and the fact that 88% of employees recently defined as
infected by TST tested negative with the T-SPOT.TB test
calls for further studies of kinetics and immune mecha-
nisms in TB infection. In our study all five T-SPOT.TB-pos-
itive individuals also had a strong positive TST. Nienhaus
et all found that 5.1% of the HCWs in three German hos-
pitals had a negative TST and a positive QFT [14]. While
the combination of a negative IGRA and a positive TST is
largely explained by prior BCG immunisation and TST
boostering, the other combination is not readily
explained, and further research is needed.
In contrast to most other studies related to TB transmis-
sion within health institutions, we have in this work com-
pared the performance of T-SPOT.TB and TST in a group
of HCWs with well-defined short-term exposure to conta-
gious TB patients in a hospital setting. In addition, the
results have been used to evaluate the role of IGRAs in
improving the surveillance of TB transmission to health
personnel in a low-incidence country like Norway.
Provided that the T-SPOT.TB results are the most reliable
compared to TST results, our study indicates that the risk
of infection among health care workers after short-term
exposure to TB patients in a hospital setting is low (2%).
This somewhat contradicts the findings of a Swiss long-
term institutional study in which 15% of contacts were T-
SPOT.TB-positive after prolonged unprotected exposure
[13]. Although both studies were performed in health care
institutions in low incidence countries, the exposure time
may account for the observed differences in transmission.
A study from Denmark also reported a low proportion
(1%) of latent TB among HCWs as detected by the QFT
test [10]. However, these data were not based on recent
exposure, but rather represent the general prevalence level
among hospital personnel working in departments with
TB patients. We found a prevalence level of 3% in our
cohort. Not surprisingly, these results are in contrast to
findings from a high-endemic country like Russia, where
a study utilizing QFT revealed a prevalence level of 41%
among hospital staff working with infectious diseases
[22]. Several reports based on TST conversion indicate
that the risk of being infected may be high, even within a
limited time frame of exposure [23,24]. This has also been
Distribution of Mantoux test results by mm induration  among 155 exposed health care workers and 48 healthy con- trols Figure 1
Distribution of Mantoux test results by mm indura-
tion among 155 exposed health care workers and 48 
healthy controls. Left columns: percent of total number of 
exposed health care workers (HCWs). Right columns: per-
cent of total number of healthy controls. HCWs with a pre-
vious positive TST (by Mantoux test ≥ 10 mm increase or ≥ 
15 mm if previously unknown) where not retested, but were 
counted as ≥ 15 mm. The distribution of T-SPOT.TB posi-
tives is indicated by white circles; all of these 5 HCWs had ≥ 
15 mm induration or were vesicular.
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confirmed by a T-SPOT.TB study in Italy in which 32% of
the staff in a maternity ward became positive for TB after
a mean exposure time of 6 hours [19]. Compared to these
findings, our study detected a low degree of transmission.
However, it should be noted that the majority of the indi-
viduals in this study had been exposed for less than 8
hours before precautions were taken. Still, among the
three persons with positive T-SPOT.TB tests (believed to
be recently infected), two were exposed for less than 8
hours. The absence of a statistically significant correlation
between exposure time and both TST and T-SPOT.TB
results is probably due to both the low exposure time and
the small number of participants, since these correlations
have been demonstrated in many other studies
[19,23,24].
Importantly, the results indicate that using IGRAs as an
alternative to the present follow-up strategy based on TST
results could save substantial resources. Although TST by
itself will be less expensive than a comprehensive labora-
tory procedure, the utilization of Mtb-specific blood tests
has the potential to save major resources as the number of
persons who must be followed up for 3 years can be
reduced by up to 88%. In this context, the possibility of
avoiding unnecessary and costly treatment, including seri-
ous side effects, is also of considerable importance. In
addition, most exposed health care workers will avoid
long-term anxiety by obtaining a negative result at a very
early investigational stage. Finally, the small number of
infected persons who require treatment can be identified
immediately.
Oxlade et al. performed a 20-year cost-benefit analysis
that used Markov modelling to compare the costs of TB
screening with different strategies among hypothetical
cohorts of foreign-born immigrants to Canada and con-
tacts of TB cases. Model inputs were derived from pub-
lished literature and utilization of the QFT test. For
entering immigrants, screening with Chest X-Ray would
be the most cost-effective and QFT the least cost-effective
strategy. Sequential screening with TST followed by QFT
was more cost-effective than either QFT or TST alone. In
contact tracing after exposure, however, screening with
TST followed by QFT, if positive, was more cost-effective
than any other strategy. This was largely because TST alone
was not effective if the exposed group had been vaccinated
with BCG after infancy [25]. These findings were also con-
firmed by a Swiss study by Wrighton-Smith et al., estimat-
ing the costs of screening a cohort of 1000 individuals for
latent tuberculosis; screening with TST alone followed by
Chest X-Ray and clinical follow up of the positive cases
was estimated to  695820; T-SPOT.TB  alone was esti-
mated to  387135; TST followed by T-SPOT.TB of the pos-
itives was estimated to  342563, i.e. the less costly [26].
Due to the fact that BCG immunization has been admin-
istered routinely in Norway, specific blood tests should be
introduced in all post-exposure contact tracing situations.
Because TB transmission to health personnel in Norway
seems to be rather low, the two-step screening approach
(TST followed by IGRA) might be attractive. However,
some studies indicate an unacceptable low sensitivity of
TST; Nienhaus et al. found that 40% of the HCW with
latent TB infection according to IGRA results had a nega-
tive TST, and would have been missed utilizing TST fol-
lowed by QFT of the TST positives. There is also evidence
that a positive IGRA is a much better predictor of future
reactivation than a positive TST [27], which is of particular
interest because the Norwegian guidelines recommend
prophylactic treatment in all documented cases of latent
TB infection aged < 35 years. Further research is obviously
needed to define improved screening strategies in low-
endemic settings, both in the light of sensitivity and cost-
effectiveness.
It should also be noted that the QFT method, although
less sensitive in immuno-suppressed individuals, has
both logistic and economic advantages compared to the
T-SPOT.TB assay, and implementation of the QFT test has
recently been suggested in Norway's national guidelines.
The introduction of specific T-cell based assays for post-
exposure screening and subsequent prophylactic treat-
ment will become a rational and important component of
the national TB control strategy.
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